SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Auspex Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information

Loading...
Loading...
STEVENSON, Md.--(BUSINESS WIRE)--

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Auspex Pharmaceuticals, Inc. ("Auspex" or the "Company") ASPX relating to the proposed buyout of the Company by Teva Pharmaceuticals Industries Ltd. ("Teva").

Under the terms of the transaction, Auspex shareholders are anticipated to receive $101.00 in cash for each share of Auspex common stock held. The firm's investigation seeks to determine, among other things, whether the Company's Board of Directors failed to satisfy their duties to shareholders, including whether the Board adequately pursued alternatives to the acquisition and whether the Board obtained the best price possible for the Company's shares of common stock. In particular, according to Yahoo! Finance, at least one Wall Street analyst has issued a price target for Auspex stock at $105.00 per share.

If you currently own common stock of Auspex and would like to learn more about the investigation being conducted by Brower Piven, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentinvestigations.html. You may also request more information by contacting Brower Piven either by email at hoffman@browerpiven.com or by telephone at (410) 415-6616.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.

Brower Piven, A Professional Corporation
Charles J. Piven, 410-415-6616
1925 Old Valley Road
Stevenson, Maryland 21153
hoffman@browerpiven.com

Loading...
Loading...
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...